AIM ImmunoTech Inc. Logo

AIM ImmunoTech Inc.

Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.

AIM | NYSE

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
2117 SW HIGHWAY 484, 32801 OCALA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for cancers, immune disorders, and viral diseases. The company's lead program is Ampligen® (rintatolimod), a proprietary immuno-modulator that has demonstrated broad-spectrum activity and is being evaluated in clinical studies for various debilitating and life-threatening conditions. AIM ImmunoTech is dedicated to advancing therapeutic solutions by leveraging immunology to address unmet medical needs. The company was formerly known as Hemispherx Biopharma.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all AIM ImmunoTech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AIM ImmunoTech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AIM ImmunoTech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030

Talk to a Data Expert

Have a question? We'll get back to you promptly.